{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T22:28:08Z","timestamp":1771367288511,"version":"3.50.1"},"reference-count":24,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: The role of denosumab in patients with resectable giant cell tumour of bone remains unclear. We asked the following research question: for patients (aged \u2265 12 years) with resectable giant cell tumour of bone, what are the benefits and harms of denosumab compared with no denosumab in terms of (1) facilitation of surgery (operative time, blood loss), (2) disease recurrence, (3) pain control, (4) disease stability, and (5) adverse effects (e.g., malignant transformation, osteonecrosis of jaw, atypical femur fracture)? One previous systematic review addressed only one outcome\u2014disease recurrence. Therefore, we undertook this new systematic review to address the above five outcomes. Methods: MEDLINE, EMBASE, PubMed, and Cochrane Database of Systematic Reviews databases were searched on June 30, 2020. Results: This systematic review included one previous systematic review and five comparative studies. Due to poor quality, non-randomized studies fraught with selection bias, it is difficult to determine if a significant difference exists in the outcomes for surgical giant cell tumour of bone with perioperative denosumab. There were no reported cases of adverse effects from denosumab. Conclusion: To date, there is insufficient evidence to understand the value of denosumab in the perioperative setting in patients with giant cell tumour of bone.<\/jats:p>","DOI":"10.3390\/curroncol28020124","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T11:13:26Z","timestamp":1616411606000},"page":"1302-1313","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review"],"prefix":"10.3390","volume":"28","author":[{"given":"Abha","family":"Gupta","sequence":"first","affiliation":[{"name":"Division of Haematology\/Oncology, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Durocher-Allen","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Snezana","family":"Popovic","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Tozer","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-3758","authenticated-orcid":false,"given":"Xiaomei","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada"},{"name":"Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Ghert","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2017.02.021","article-title":"Giant cell tumour of bone in the denosumab era","volume":"77","author":"Dijkstra","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.3747\/co.20.1497","article-title":"Denosumab and giant cell tumour of bone-a review and future management considerations","volume":"20","author":"Xu","year":"2013","journal-title":"Curr. Oncol."},{"key":"ref_3","first-page":"2","article-title":"Giant Cell Tumor of Bone\u2014An Overview","volume":"4","author":"Sobti","year":"2016","journal-title":"Arch. Bone. Jt. Surg."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.01.006","article-title":"Efficacy of denosumab in joint preservation for patients with giant cell tumour of the bone","volume":"59","author":"Traub","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ejso.2018.03.020","article-title":"Denosumab treatment of inoperable or locally advanced giant cell tumor of bone\u2014Multicenter analysis outside clinical trial","volume":"44","author":"Rutkowski","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: An open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1007\/s00264-017-3536-9","article-title":"How safe and effective is denosumab for bone giant cell tumour?","volume":"41","author":"Errani","year":"2017","journal-title":"Int. Orthop."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jclinepi.2015.06.005","article-title":"ROBIS: A new tool to assess risk of bias in systematic reviews was developed","volume":"69","author":"Whiting","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sterne, J.A.C., Hernan, M.A., Reeves, B.C., Savovic, J., Berkman, N.D., Viswanathan, M., Herry, D., Altman, D.G., Ansari, M.T., and Boutron, I. (2016). ROBINS-I: A Tool for Assessing Risk of Bias in Non-Randomized Studies of Interventions. BMJ, 355.","DOI":"10.1136\/bmj.i4919"},{"key":"ref_13","unstructured":"StataCorp (2017). Stata Statistical Software: Release 15.1 2017, StataCorp LP."},{"key":"ref_14","unstructured":"Biermann, J.S., Chow, W., Boles, S., Brigman, B., Callan, A.K., Cranmer, L.D., Dianat, S., Dommelly, E., Fabbri, N., and Getty, P. (2021, March 19). National Clinical Practice Guidelines in Oncology. Bone Cancer. Version 1. 2021 [internet]. Pennsylvania: National Clinical Practice Guidelines. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1097\/BRS.0000000000001818","article-title":"Benign tumors of the spine: Has new chemotherapy and interventional radiology changed the treatment paradigm?","volume":"41","author":"Boriani","year":"2016","journal-title":"Spine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/CORR.0000000000001074","article-title":"Is Treatment with Denosumab Associated with Local Recurrence in Patients with Giant Cell Tumor of Bone Treated with Curettage? A Systematic Review","volume":"478","author":"Tsukamoto","year":"2020","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s11999.0000000000000243","article-title":"Does Denosumab Change the Giant Cell Tumor Treatment Strategy? Lessons Learned From Early Experience","volume":"476","author":"Agarwal","year":"2018","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1302\/0301-620X.102B2.BJJ-2019-0813.R1","article-title":"Retrospective cohort study of 68 sacral giant cell tumours treated with nerve-sparing surgery and evaluation on therapeutic benefits of denosumab therapy","volume":"102\u2013B","author":"Lim","year":"2020","journal-title":"Bone Jt. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1302\/0301-620X.100B12.BJJ-2018-0189.R2","article-title":"Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture","volume":"100\u2013B","author":"Medellin","year":"2018","journal-title":"Bone Jt. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s11999.0000000000000104","article-title":"Preoperative denosumab with curettage and cryotherapy in giant cell tumor of bone: Is there an increased risk of local recurrence?","volume":"476","author":"Scoccianti","year":"2018","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00264-018-4085-6","article-title":"Denosumab does not decrease the risk of lung metastases from bone giant cell tumour","volume":"43","author":"Tsukamoto","year":"2019","journal-title":"Int. Orthop."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2106\/JBJS.17.00057","article-title":"Denosumab may increase the risk of local recurrence in patients with giant-cell tumor of bone treated with curettage","volume":"100","author":"Errani","year":"2018","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12957-018-1459-6","article-title":"Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: From a questionnaire for JCOG 1610 study","volume":"16","author":"Urakawa","year":"2018","journal-title":"World J. Surg. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1200\/JCO.2018.36.15_suppl.11521","article-title":"Neoadjuvant denosumab for the treatment of resectable giant cell tumor of bone: First results of Russian multicenter study","volume":"36","author":"Fedenko","year":"2018","journal-title":"J. Clin. Oncol. Conf."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/2\/124\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:39:08Z","timestamp":1760161148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/2\/124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["curroncol28020124"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28020124","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]}}}